New data out of the AATS Annual Meeting identified significant potential for a new treatment strategy. 

Data from BENEFIT-HF, a new randomized study of CVRx's implantable Barostim device, could open up access to many more heart failure patients. 

When heart patients require aortic valve replacement, would they be a better fit for TAVR or SAVR? Such decisions are not made lightly, clinicians emphasized in a new joint statement.

The FDA first shared a warning about this issue back in April. Now, the agency has shared a critical update. 

“Technology grows and grows,” as one lab director explained. “Our job is to keep up with it and use it in the most efficient and effective way.”

As TAVR continues to gain popularity, researchers remain focused on discovering new ways to predict short- and long-term outcomes. One recent study, for example, explored the potential of AI-enabled imaging assessments. Another analysis focused on the CALLY index.

Cerebral embolic protection devices are "compelling," researchers wrote, but current data does not suggest they make a significant impact on patient outcomes.

Both treatment options are effective, but metabolic and bariatric surgery was linked to more significant cardiovascular risk reductions than GLP-1 medications.

When a TAVR valve fails and that patient undergoes redo TAVR, are there benefits to choosing one device type over the other? The team behind a new study tracked multiple outcomes and identified specific factors that may help predict survival. 

The move, once finalized, helps Johnson & Johnson add multiple FDA-approved technologies to its EP portfolio.